ArticleScientific reports2016
Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 174 citations in OpenAlex.
- Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a DClinical pharmacology in drug development · 2022Trial
- Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.Scientific reports · 2019Trial
- Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs.Clinical pharmacology and therapeutics · 2026Article
- Identifying Sex Differences in Adverse Events Reported on Opioid Drugs in the FDA's Adverse Event Reporting System (FAERS).Pharmaceuticals (Basel, Switzerland) · 2026Article
- In-hospital outcomes and temporal analysis of paralyzed patients with acute myocardial infarction undergoing percutaneous coronary intervention.Scientific reports · 2026Article
- Revealing Sex Differences in Hypertensive Urgency Management: Insights From a Tertiary Hospital.Journal of clinical hypertension (Greenwich, Conn.) · 2026Observational
- Article
- A multidimensional investigation of myelosuppression associated with sintilimab: integrating pharmacovigilance signal mining with real-world clinical evidence.Frontiers in pharmacology · 2026Article
- Adverse events related to drug-drug interactions in tocilizumab combination therapy: a retrospective analysis and clinical implications.Frontiers in medicine · 2026Article
- Drug-associated insomnia and sex-specific disproportionality in the FDA adverse event reporting system (2019-Q1 2025).Frontiers in pharmacology · 2026Article
- Gender Diversity of Research Teams and Clinical Trial Enrollment.JAMA network open · 2025Article
- Evidence of Sex-Related Pharmacodynamic Differences in Photosensitive Epilepsy Treated with Valproate: Findings from a Retrospective, Observational, Single-Center, Within-Patient, Cohort Study.Drugs - real world outcomes · 2025Article
- Analysis of sex-differential gene expression on the target of approved drug.Scientific reports · 2025Article
- Benchmarking bias in embeddings of healthcare AI models: using SD-WEAT for detection and measurement across sensitive populations.BMC medical informatics and decision making · 2025Article
- Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system.Acta diabetologica · 2025Article
- A Real-world Pharmacovigilance Study Of FDA Adverse Event Reporting System (FAERS) Events For Gender Of Voriconazole Drugs.Drug research · 2025Article
- Article
- Metabolic Messengers: oestradiol.Nature metabolism · 2025Review
- Pain in women: bridging the gender pain gap.Pain reports · 2025Article
- Development and Validation of an Approach to Assessing Clinical Relevance of Potential Drug-Drug Interactions Inducing Rare but Serious Adverse Events.Clinical and translational science · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Increasing evidence has shown that sex differences exist in Adverse Drug Events (ADEs). Identifying those sex differences in ADEs could reduce the experience of ADEs for patients and could be conducive to the development of personalized medicine. In this study, we analyzed a normalized US Food and Drug Administration Adverse Event Reporting System (FAERS). Chi-squared test was conducted to discover which treatment regimens or drugs had sex differences in adverse events. Moreover, reporting odds ratio (ROR) and P value were calculated to quantify the signals of sex differences for specific drug-event combinations. Logistic regression was applied to remove the confounding effect from the baseline sex difference of the events. We detected among 668 drugs of the most frequent 20 treatment regimens in the United States, 307 drugs have sex differences in ADEs. In addition, we identified 736 unique drug-event combinations with significant sex differences. After removing the confounding effect from the baseline sex difference of the events, there are 266 combinations remained. Drug labels or previous studies verified some of them while others warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.